Neuronal aggregates are associated with phenotypic onset in the R6/2 Huntington's disease transgenic mouse

Behavioural Brain Research

Volumn 229, Issue 2, 2012, Pages 308-319

  Cowin, Randi Michelle ^a,c   Roscic, Ana ^b   Bui, Nghiem ^a,c   Graham, Deanna ^a,c   Paganetti, Paolo ^b,d   Jankowsky, Joanna L ^a,c   Weiss, Andreas ^b   Paylor, Richard ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c One Baylor Plaza ^*  (United States)

^d AC IMMUNE SA   (Switzerland)

Author keywords

Aggregation; CAG repeats; Huntington's disease; Polyglutamine; R6 2 mouse

Indexed keywords

HUNTINGTIN; MUTANT PROTEIN; POLYGLUTAMINE; TRINUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BODY WEIGHT; BRAIN CORTEX; BRAIN NERVE CELL; CELL NUCLEUS; CONGENIC STRAIN; CONTROLLED STUDY; CORPUS STRIATUM; FEAR; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE; GENE EXPRESSION; HDH GENE; HTT GENE; HUNTINGTON CHOREA; LEARNING DISORDER; LIGHT DARK EXPLORATION TASK; MALE; MEMORY; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NEUROPSYCHOLOGICAL TEST; NONHUMAN; ONSET AGE; OPEN FIELD BEHAVIOR; PHENOTYPE; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; REARING; SENSORY GATING; TRANSGENE; TRANSGENIC MOUSE; TRINUCLEOTIDE REPEAT;

AGE OF ONSET; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; FEAR; HUMANS; HUNTINGTON DISEASE; MALE; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; MOTOR SKILLS; MUTATION; NERVE TISSUE PROTEINS; NEURONS; PEPTIDES; PHENOTYPE; PROTEINS; SENSORY GATING; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84857784547     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.12.045     Document Type: Article

References (83)

1. Andrew S.E., Goldberg Y.P., Kremer B., Telenius H., Theilmann J., Adam S., et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet 1993, 4:398-403.
2. Duyao M., Ambrose C., Myers R., Novelletto A., Persichetti F., Frontali M., et al. Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet 1993, 4:387-392.
3. Snell R.G., MacMillan J.C., Cheadle J.P., Fenton I., Lazarou L.P., Davies P., et al. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat Genet 1993, 4:393-397.
4. Stine O.C., Pleasant N., Franz M.L., Abbott M.H., Folstein S.E., Ross C.A. Correlation between the onset age of Huntington's disease and length of the trinucleotide repeat in IT-15. Hum Mol Genet 1993, 2:1547-1549.
5. Brinkman R.R., Mezei M.M., Theilmann J., Almqvist E., Hayden M.R. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet 1997, 60:1202-1210.
6. Telenius H., Kremer H.P., Theilmann J., Andrew S.E., Almqvist E., Anvret M., et al. Molecular analysis of juvenile Huntington disease: the major influence on (CAG)n repeat length is the sex of the affected parent. Hum Mol Genet 1993, 2:1535-1540.
7. Squitieri F., Cannella M., Simonelli M. CAG mutation effect on rate of progression in Huntington's disease. Neurol Sci 2002, 23(Suppl. 2):S107-S108.
8. Hackam A.S., Wellington C.L., Hayden M.R. The fatal attraction of polyglutamine-containing proteins. Clin Genet 1998, 53:233-242.
9. Martindale D., Hackam A., Wieczorek A., Ellerby L., Wellington C., McCutcheon K., et al. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat Genet 1998, 18:150-154.
10. Chen S., Ferrone F.A., Wetzel R. Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation. Proc Natl Acad Sci USA 2002, 99:11884-11889.
11. Barton S., Jacak R., Khare S.D., Ding F., Dokholyan N.V. The length dependence of the polyQ-mediated protein aggregation. J Biol Chem 2007, 282:25487-25492.
12. Group HsDCR A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993, 72:971-983.
13. Brustovetsky N., LaFrance R., Purl K.J., Brustovetsky T., Keene C.D., Low W.C., et al. Age-dependent changes in the calcium sensitivity of striatal mitochondria in mouse models of Huntington's disease. J Neurochem 2005, 93:1361-1370.
14. Hodgson J.G., Agopyan N., Gutekunst C.A., Leavitt B.R., LePiane F., Singaraja R., et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 1999, 23:181-192.
15. Schilling G., Becher M.W., Sharp A.H., Jinnah H.A., Duan K., Kotzuk J.A., et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 1999, 8:397-407.
16. Wheeler V.C., Auerbach W., White J.K., Srinidhi J., Auerbach A., Ryan A., et al. Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum Mol Genet 1999, 8:115-122.
17. Shelbourne P.F., Killeen N., Hevner R.F., Johnston H.M., Tecott L., Lewandoski M., et al. A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Hum Mol Genet 1999, 8:763-774.
18. Wheeler V.C., White J.K., Gutekunst C.A., Vrbanac V., Weaver M., Li X.J., et al. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet 2000, 9:503-513.
19. Laforet G.A., Sapp E., Chase K., McIntyre C., Boyce F.M., Campbell M., et al. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J Neurosci 2001, 21:9112-9123.
20. Lin C.H., Tallaksen-Greene S., Chien W.M., Cearley J.A., Jackson W.S., Crouse A.B., et al. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum Mol Genet 2001, 10:137-144.
21. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
22. Hockly E., Woodman B., Mahal A., Lewis C.M., Bates G. Standardization and statistical approaches to therapeutic trials in the R6/2 mouse. Brain Res Bull 2003, 61:469-479.
23. Morton A.J., Glynn D., Leavens W., Zheng Z., Faull R.L., Skepper J.N., et al. Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice. Neurobiol Dis 2009, 33:331-341.
24. Dragatsis I., Goldowitz D., Del Mar N., Deng Y.P., Meade C.A., Liu L., et al. CAG repeat lengths > or =335 attenuate the phenotype in the R6/2 Huntington's disease transgenic mouse. Neurobiol Dis 2009, 33:315-330.
25. Menalled L., El-Khodor B.F., Patry M., Suarez-Farinas M., Orenstein S.J., Zahasky B., et al. Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol Dis 2009, 35:319-336.
26. Tang B., Seredenina T., Coppola G., Kuhn A., Geschwind D.H., Luthi-Carter R., et al. Gene expression profiling of R6/2 transgenic mice with different CAG repeat lengths reveals genes associated with disease onset and progression in Huntington's disease. Neurobiol Dis 2011, 42:459-467.
27. Zoghbi H.Y., Orr H.T. Glutamine repeats and neurodegeneration. Annu Rev Neurosci 2000, 23:217-247.
28. Jenkins B.G., Andreassen O.A., Dedeoglu A., Leavitt B., Hayden M., Borchelt D., et al. Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease. J Neurochem 2005, 95:553-562.
29. Hansson O., Castilho R.F., Korhonen L., Lindholm D., Bates G.P., Brundin P. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length. J Neurochem 2001, 78:694-703.
30. Bolivar V.J., Caldarone B.J., Reilly A.A., Flaherty L. Habituation of activity in an open field: a survey of inbred strains and F1 hybrids. Behav Genet 2000, 30:285-293.
31. Crawley J.N., Belknap J.K., Collins A., Crabbe J.C., Frankel W., Henderson N., et al. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology (Berl) 1997, 132:107-124.
32. Rogers D.C., Jones D.N., Nelson P.R., Jones C.M., Quilter C.A., Robinson T.L., et al. Use of SHIRPA and discriminant analysis to characterise marked differences in the behavioural phenotype of six inbred mouse strains. Behav Brain Res 1999, 105:207-217.
33. Spencer C.M., Alekseyenko O., Hamilton S.M., Thomas A.M., Serysheva E., Yuva-Paylor L.A., et al. Modifying behavioral phenotypes in Fmr1KO mice: genetic background differences reveal autistic-like responses. Autism Res 2011, 4:40-56.
34. Cowin RM, Bui N, Graham D, Green JR, Grueninger S, Yuva-Paylor LA, et al. Onset and progression of behavioral and molecular phenotypes in a novel congenic R6/2 line exhibiting intergenerational CAG repeat stability. PLoS ONE 6(12): e28409, doi:10.1371/journal.pone.0028409.
35. Mathis C., Paul S.M., Crawley J.N. Characterization of benzodiazepine-sensitive behaviors in the A/J and C57BL/6J inbred strains of mice. Behav Genet 1994, 24:171-180.
36. Treit D., Fundytus M. Thigmotaxis as a test for anxiolytic activity in rats. Pharmacol Biochem Behav 1988, 31:959-962.
37. Crawley J., Goodwin F.K. Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 1980, 13:167-170.
38. Zeyda T., Diehl N., Paylor R., Brennan M.B., Hochgeschwender U. Impairment in motor learning of somatostatin null mutant mice. Brain Res 2001, 906:107-114.
39. Klivenyi P., Bende Z., Hartai Z., Penke Z., Nemeth H., Toldi J., et al. Behaviour changes in a transgenic model of Huntington's disease. Behav Brain Res 2006, 169:137-141.
40. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002, 3. RESEARCH0034.
41. Weiss A., Abramowski D., Bibel M., Bodner R., Chopra V., DiFiglia M., et al. Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington's disease. Anal Biochem 2009, 395:8-15.
42. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:e45.
43. Pfaffl M.W., Horgan G.W., Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002, 30:e36.
44. Bates G., Harper P., Jones L. Huntington's disease 2002, Oxford University Press, Oxford. 3rd ed.
45. Carter R.J., Lione L.A., Humby T., Mangiarini L., Mahal A., Bates G.P., et al. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 1999, 19:3248-3257.
46. Bolt M.W., Mahoney P.A. High-efficiency blotting of proteins of diverse sizes following sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anal Biochem 1997, 247:185-192.
47. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997, 90:537-548.
48. Garfin D.E. One-dimensional gel electrophoresis. Methods in enzymology 1990, Academic Press, p. 429. M.P. Deutscher (Ed.).
49. Lovestone S., Hodgson S., Sham P., Differ A.M., Levy R. Familial psychiatric presentation of Huntington's disease. J Med Genet 1996, 33:128-131.
50. Tsuang D., Almqvist E.W., Lipe H., Strgar F., DiGiacomo L., Hoff D., et al. Familial aggregation of psychotic symptoms in Huntington's disease. Am J Psychiatry 2000, 157:1955-1959.
51. Tsuang D., DiGiacomo L., Lipe H., Bird T.D. Familial aggregation of schizophrenia-like symptoms in Huntington's disease. Am J Med Genet 1998, 81:323-327.
52. Hickey M.A., Gallant K., Gross G.G., Levine M.S., Chesselet M.F. Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing. Neurobiol Dis 2005, 20:1-11.
53. Lione L.A., Carter R.J., Hunt M.J., Bates G.P., Morton A.J., Dunnett S.B. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J Neurosci 1999, 19:10428-10437.
54. Naver B., Stub C., Moller M., Fenger K., Hansen A.K., Hasholt L., et al. Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse. Neuroscience 2003, 122:1049-1057.
55. Pouladi M.A., Graham R.K., Karasinska J.M., Xie Y., Santos R.D., Petersen A., et al. Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain 2009, 132:919-932.
56. Van Raamsdonk J.M., Pearson J., Slow E.J., Hossain S.M., Leavitt B.R., Hayden M.R. Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. J Neurosci 2005, 25:4169-4180.
57. Erway L.C., Willott J.F., Archer J.R., Harrison D.E. Genetics of age-related hearing loss in mice: I. Inbred and F1 hybrid strains. Hear Res 1993, 65:125-132.
58. Brooks S., Higgs G., Janghra N., Jones L., Dunnett S.B. Longitudinal analysis of the behavioural phenotype in YAC128 (C57BL/6J) Huntington's disease transgenic mice. Brain Res Bull 2010, 10.1016/j.brainresbull.2010.05.005.
59. Brooks S.P., Janghra N., Workman V.L., Bayram-Weston Z., Jones L., Dunnett S.B. Longitudinal analysis of the behavioural phenotype in R6/1 (C57BL/6J) Huntington's disease transgenic mice. Brain Res Bull 2011, 10.1016/j.brainresbull.2011.01.010.
60. Benn C.L., Luthi-Carter R., Kuhn A., Sadri-Vakili G., Blankson K.L., Dalai S.C., et al. Environmental enrichment reduces neuronal intranuclear inclusion load but has no effect on messenger RNA expression in a mouse model of Huntington disease. J Neuropathol Exp Neurol 2010, 69:817-827.
61. Carter R.J., Hunt M.J., Morton A.J. Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene. Mov Disord 2000, 15:925-937.
62. Hockly E., Cordery P.M., Woodman B., Mahal A., van Dellen A., Blakemore C., et al. Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann Neurol 2002, 51:235-242.
63. van Dellen A., Blakemore C., Deacon R., York D., Hannan A.J. Delaying the onset of Huntington's in mice. Nature 2000, 404:721-722.
64. van Dellen A., Cordery P.M., Spires T.L., Blakemore C., Hannan A.J. Wheel running from a juvenile age delays onset of specific motor deficits but does not alter protein aggregate density in a mouse model of Huntington's disease. BMC Neurosci 2008, 9:34.
65. Bottomly D., Walter N.A., Hunter J.E., Darakjian P., Kawane S., Buck K.J., et al. Evaluating gene expression in C57BL/6J and DBA/2J mouse striatum using RNA-Seq and microarrays. PLoS ONE 2011, 6:e17820.
66. Ghazalpour A., Bennett B., Petyuk V.A., Orozco L., Hagopian R., Mungrue I.N., et al. Comparative analysis of proteome and transcriptome variation in mouse. PLoS Genet 2011, 7:e1001393.
67. Korostynski M., Kaminska-Chowaniec D., Piechota M., Przewlocki R. Gene expression profiling in the striatum of inbred mouse strains with distinct opioid-related phenotypes. BMC Genomics 2006, 7:146.
68. Hackam A.S., Singaraja R., Wellington C.L., Metzler M., McCutcheon K., Zhang T., et al. The influence of huntingtin protein size on nuclear localization and cellular toxicity. J Cell Biol 1998, 141:1097-1105.
69. Gorlich D., Mattaj I.W. Nucleocytoplasmic transport. Science 1996, 271:1513-1518.
70. Suntharalingam M., Wente S.R. Peering through the pore: nuclear pore complex structure, assembly, and function. Dev Cell 2003, 4:775-789.
71. Terry L.J., Shows E.B., Wente S.R. Crossing the nuclear envelope: hierarchical regulation of nucleocytoplasmic transport. Science 2007, 318:1412-1416.
72. Benn C.L., Landles C., Li H., Strand A.D., Woodman B., Sathasivam K., et al. Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease. Hum Mol Genet 2005, 14:3065-3078.
73. Kitamura A., Kubota H., Pack C.G., Matsumoto G., Hirayama S., Takahashi Y., et al. Cytosolic chaperonin prevents polyglutamine toxicity with altering the aggregation state. Nat Cell Biol 2006, 8:1163-1170.
74. Sanchez I., Mahlke C., Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 2003, 421:373-379.
75. Wang C.E., Zhou H., McGuire J.R., Cerullo V., Lee B., Li S.H., et al. Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin. J Cell Biol 2008, 181:803-816.
76. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
77. Jackson W.S., Tallaksen-Greene S.J., Albin R.L., Detloff P.J. Nucleocytoplasmic transport signals affect the age at onset of abnormalities in knock-in mice expressing polyglutamine within an ectopic protein context. Hum Mol Genet 2003, 12:1621-1629.
78. Li H., Li S.H., Cheng A.L., Mangiarini L., Bates G.P., Li X.J. Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. Hum Mol Genet 1999, 8:1227-1236.
79. Peters M.F., Nucifora F.C., Kushi J., Seaman H.C., Cooper J.K., Herring W.J., et al. Nuclear targeting of mutant Huntingtin increases toxicity. Mol Cell Neurosci 1999, 14:121-128.
80. Yang W., Dunlap J.R., Andrews R.B., Wetzel R. Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum Mol Genet 2002, 11:2905-2917.
81. Myers R.H. Huntington's disease genetics. NeuroRx 2004, 1:255-262.
82. Nance M.A., Mathias-Hagen V., Breningstall G., Wick M.J., McGlennen R.C. Analysis of a very large trinucleotide repeat in a patient with juvenile Huntington's disease. Neurology 1999, 52:392-394.
83. Nicolas G., Devys D., Goldenberg A., Maltete D., Herve C., Hannequin D., et al. Juvenile Huntington disease in an 18-month-old boy revealed by global developmental delay and reduced cerebellar volume. Am J Med Genet A 2011, 155A:815-818.